drugset / Trial / NCT06421714

A Study of the Safety, Tolerability, and Pharmacokinetics of Orally Administered Venglustat and Itraconazole in Healthy Adult Male Participants

NCT06421714

Phase 1 Completed 8 enrolled Genzyme, a Sanofi Company
Non-randomizedSingle-groupOpen-labelTreatment

Summary

The purpose of this study is to assess in healthy adult male participants the effects of itraconazole on the pharmacokinetics of venglustat and to assess the safety and tolerability of venglustat with and without coadministration of itraconazole. The maximum duration for participants from screening is between 32 to 62 days.

Timeline

Start
2018-08-16
Primary completion
2018-10-14
Completion
2018-10-14

Drugs

EvaluationDrugModalityDoseRoute
Subject Itraconazole Small molecule Oral
Subject Venglustat Small molecule Oral

Indications

No indication recorded.